Intermediate-1, Intermediate-2 and High Risk MDS
Showing 1 - 25 of >10,000
MDS Trial (Decitabine/Cedazuridine, Magrolimab)
Not yet recruiting
- Myelodysplastic Syndromes
- (no location specified)
Apr 18, 2023
Acute Myeloid Leukemia, Myelodysplastic Tumor Trial (Magrolimab, 7+3, CPX-351)
Not yet recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Neoplasm
- Magrolimab
- +2 more
- (no location specified)
Apr 24, 2023
Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R Trial in Canada, United States (Etavopivat)
Recruiting
- Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
-
Ocala, Florida
- +3 more
Jan 30, 2023
AML, MDS, Old Age; Debility Trial in Suzhou (Azacitidine, all trans retinoic acid)
Recruiting
- AML
- +3 more
- Azacitidine
- all trans retinoic acid
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Dec 27, 2021
Pre-fibrotic Myelofibrosis Trial in Taipei, Taiwan, 100 (Ropeginterferon Alfa-2B Prefilled Syringe [Besremi])
Recruiting
- Pre-fibrotic Myelofibrosis
- Ropeginterferon Alfa-2B Prefilled Syringe [Besremi]
-
Taipei, Taiwan, 100, TaiwanNational Taiwan University Hospital
Feb 7, 2023
MDS Trial in Bronx (Pyrimethamine)
Withdrawn
- Myelodysplastic Syndromes
-
Bronx, New YorkMontefiore Medical Center
Sep 15, 2021
Myelofibrosis Trial in Hangzhou (Jaktinib, Placebo to match Hydroxycarbamide, Hydroxycarbamide Tablets)
Recruiting
- Myelofibrosis
- Jaktinib
- +3 more
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital of Medical School of Zhejiang Univ
Nov 28, 2022
Pulmonary Embolism Trial in Milano (ultrasound-assisted, catheter-directed thrombolysis)
Recruiting
- Pulmonary Embolism
- ultrasound-assisted, catheter-directed thrombolysis
-
Milano, Italia, ItalyASST GOM Niguarda
Nov 21, 2023
Intermediate to High-risk Asymptomatic Sportsmen With Exercise
Completed
- Electrocardiography
- Screening stress test on a bicycle ergometer (usual practise)
-
Saint-Étienne, FranceCentre Hospitalier de Saint-Etienne
Sep 6, 2023
MDS Trial in Beijing (Hetrombopag, Stanozolol Tablets)
Not yet recruiting
- MDS
- Hetrombopag
- Stanozolol Tablets
-
Beijing, ChinaPeking Union Medical College Hospital
Sep 18, 2021
Prostatic Cancer Trial (High Dose Brachytherapy, Stereostatic Body Radiation Therapy)
Not yet recruiting
- Prostatic Cancer
- High Dose Brachytherapy
- Stereostatic Body Radiation Therapy
- (no location specified)
Mar 3, 2023
MDS Trial in Miami, New York (50 gm CIVI/24 hours x 5 days every 4 week)
Recruiting
- Myelodysplastic Syndromes
- 50 gm CIVI/24 hours x 5 days every 4 week
-
Miami, Florida
- +1 more
Jul 6, 2022
Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation Trial (Olaparib, LHRH agonist)
Not yet recruiting
- Prostate Cancer
- +4 more
- Olaparib
- LHRH agonist
- (no location specified)
Aug 10, 2022
Pancreatic Fistula Trial in Cleveland (Piperacillin/Tazobactam, Amoxicillin/ Clavulanic acid)
Not yet recruiting
- Pancreatic Fistula
- Piperacillin/Tazobactam
- Amoxicillin/ Clavulanic acid
-
Cleveland, OhioUniversity Hospitals Cleveland Medical Center
Feb 22, 2023
Screening CEDM in Intermediate and High-Risk Patient Populations
Completed
- Breast Cancer
- Contrast Enhanced Digital Mammography
-
Scottsdale, ArizonaMayo Clinic in Arizona
Jan 18, 2023
MDS, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic Trial in Newcastle (Subcutaneous azacitidine, Oral
Not yet recruiting
- Myelodysplastic Syndromes
- +3 more
- Subcutaneous azacitidine
- Oral decitabine/cedazuridine
-
Newcastle, New South Wales, AustraliaCalvary Mater Newcastle
May 29, 2023
MDS Trial in Worldwide (Oral Azacitidine, Placebo for Oral Azacitidine)
Not yet recruiting
- Myelodysplastic Syndromes
- Oral Azacitidine
- Placebo for Oral Azacitidine
-
Buenos Aires, Argentina
- +1 more
Aug 1, 2022
MDS Trial in Worldwide (MBG453, Placebo, Hypomethylating agents)
Active, not recruiting
- Myelodysplastic Syndromes
- MBG453
- +2 more
-
Duarte, California
- +46 more
Jan 20, 2023
Anal Squamous Cell Carcinoma Trial (Radiotherapy - Low risk group, Radiotherapy - Standard risk group, Radiotherapy -
Not yet recruiting
- Anal Squamous Cell Carcinoma
- Radiotherapy - Low risk group
- +3 more
- (no location specified)
Sep 18, 2023